Another study by Pillay et al. has revealed that ovarian cancer cells respond differently to PARGi (PDD00017273) compared to PARP inhibitor (Olaparib) and may be dependent on DNA replication vulnerabilities in cells [34]. Here, PARP1 is linked to ovarian cancer.